Measurement Of Serum Levels Of Two Antiepileptic Drugs During Conversion In Patients With Epilepsy

This study has been completed.

First Received: August 14, 2002 Last Updated: March 7, 2006 History of Changes

Sponsored by:	GlaxoSmithKline
Information provided by:	GlaxoSmithKline
ClinicalTrials.gov Identifier:	NCT00043914

Purpose

This study includes patients 16 years of age or older with a confident diagnosis of epilepsy who are currently treated with an antiepileptic drug (AED) monotherapy but require a change in therapy due to inadequate seizure control and/or unacceptable side effects.

Condition	Intervention	Phase
Epilepsy	Drug: lamotrigine	Phase IV

Study Type:	Interventional
Study Design:	Treatment, Open Label, Uncontrolled, Single Group Assignment, Pharmacokinetics Study
Official Title:	A Multicenter, Open-Label Conversion of Valproate Monotherapy to Lamotrigine Monotherapy in Patients With Epilepsy

Resource links provided by NLM:

Genetics Home Reference related topics: pyridoxal 5'-phosphate-dependent epilepsy

MedlinePlus related topics: Epilepsy

Drug Information available for: Lamotrigine

U.S. FDA Resources

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:

Drug levels of lamotrigine.

Secondary Outcome Measures:

This study has no secondary outcome measures.

Estimated Enrollment:	72
Study Start Date:	January 2002

Eligibility

Ages Eligible for Study:	16 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

INCLUSION CRITERIA:

16 years old or older.
Have confident diagnosis of epilepsy.
Have been on the medication valproate for at least 3 months and is currently on a stable daily dose.
Male or female; females of child-bearing potential must have negative pregnancy test at screen and must agree to use an acceptable birth control method.

EXCLUSION CRITERIA:

A history of hypersensitivity to the drug being studied.
Currently being treated with or has been treated in the past with the drug being studied.
Undergoing polytherapy treatment with the medication valproate and one or more other antiepileptic drug(s).
If undergoing treatment with vagal nerve stimulation, has had device implanted more than 30 days prior to enrollment.
Has taken an investigational drug or the medication Felbatol within the previous 30 days.
Is abusing alcohol and/or other substances.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00043914

Show 24 Study Locations

Sponsors and Collaborators

GlaxoSmithKline

Investigators

Study Director:

GSK Clinical Trial, MD

GlaxoSmithKline

More Information

No publications provided

Study ID Numbers:	LAM40013
Study First Received:	August 14, 2002
Last Updated:	March 7, 2006
ClinicalTrials.gov Identifier:	NCT00043914 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by GlaxoSmithKline:

epilepsy
monotherapy conversion

Study placed in the following topic categories:

Calcium, Dietary
Epilepsy
Lamotrigine
Calcium Channel Blockers
Central Nervous System Diseases

Cardiovascular Agents
Brain Diseases
Valproic Acid
Anticonvulsants

Additional relevant MeSH terms:

Molecular Mechanisms of Pharmacological Action
Nervous System Diseases
Central Nervous System Diseases
Calcium Channel Blockers
Cardiovascular Agents
Brain Diseases
Pharmacologic Actions

Membrane Transport Modulators
Epilepsy
Therapeutic Uses
Lamotrigine
Central Nervous System Agents
Anticonvulsants

ClinicalTrials.gov processed this record on July 02, 2009